Prothena Corporation plc Overview
Pro stress-test →Prothena Corporation plc is a late-stage clinical biotechnology company focused on discovery and development of novel therapies to treat diseases caused by protein dysregulation. With expertise in protein dysregulation, the company is advancing a pipeline of both wholly-owned and partnered programs for potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
Strategic Profile
Pro stress-test →Prothena is developing and applying its proprietary CYTOPE® technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company has strategic partnerships with F. Hoffmann-La Roche Ltd. to develop and commercialize antibodies targeting a-synuclein (prasinezumab) and with Bristol Myers Squibb for antibodies targeting tau and TDP-43. As of December 31, 2025, Prothena holds $308.4M in cash with no debt and expects $255M at year-end 2026.
Competitive Landscape
Pro stress-test →Prothena operates in the biotechnology sector focusing on discovery and development of innovative therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. Key competitors include larger pharma companies (Eli Lilly, Biogen) and smaller biotech firms (Denali Therapeutics, Alector Inc.) pursuing similar neurodegenerative disease targets, particularly Alzheimer's and Parkinson's programs.
Industry Context
Prothena Corporation plc operates in Biotechnology - Clinical Stage Neurodegenerative Diseases.
Key facts
Founded: 2012 · Headquarters: Dublin, Ireland · Revenue: $9.68M · Market cap: $485.55M